Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate – Yahoo Finance
|
Bellicum Announces Initiation of Patient Dosing with Controllable CAR T-Cell Product Candidate
Yahoo Finance “The ability to control the intensity and duration of a cell-based treatment may help address the limitations that current CAR T therapies face, especially when targeting solid tumors. While our first study is in pancreatic cancer where there is great … |
